drugset / Trial / NCT01994486
Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi center study of treatment-naive non-cirrhotic subjects with genotype 1 chronic Hepatitis C Virus. All subjects will receive telaprevir (TVR) in combination with sofosbuvir (SOF) for 12 weeks.
Timeline
- Start
- 2013-12
- Primary completion
- 2014-04
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |
| Subject | Telaprevir | Small molecule | 1125 mg | Oral |